Physician Scientist @YaleDerm | #melanoma #dermpath #immunology #epigenetics #bioinformatics. Views are my own.
Joined September 2015
- Tweets286
- Following602
- Followers601
- Likes621
Pinned Tweet
Excited to announce that I will be starting my research group at @YaleMed.
If you are interested in epigenetics and cancer immunology (or know someone interested in these topics), reach out/apply: miceviclab.github.io/postdoc…
Please help spread the word!
We are excited to share a preprint of our latest study regarding targeting #DNMT1 to counteract CD8 T cell exhaustion and improve anti-tumor activity: biorxiv.org/content/10.64898…
We think DNMT1 may be a modifier of CD8 fate and epigenetic plasticity, such that inhibiting it could preserve effector competence and could make both checkpoint therapy and TIL therapy work for more patients.
Kudos to Maya Deshmukh in lab who drove the study, our lab team (Simon, Peili, Henna) and our village @FlavellLab, BosenbergLab , Anderson Lab, support by @MelanomaReAlli, the Dermatology Foundation, NCI K award & @YaleCancer.
Goran Micevic MD/PhD retweeted
Could AI change how ultrasound is used at the bedside?
Point-of-care ultrasound lets clinicians perform and interpret scans right where patients receive care. In an interview, Yale emergency medicine physician Cristiana Baloescu explains how artificial intelligence could make these tools more accurate, responsive, and useful in time-sensitive clinical settings.
Read more in Yale News: bit.ly/3Z5y4im
I am a physician scientist @YaleCancer taking care of patients with #cancer and direct a #melanoma research lab. On September 6, 2025, I am taking the fight against cancer to the streets (on a bicycle). You can join my fundraising effort here: rideclosertofree.org/partici…
Thank you!
May is #MelanomaAwarenessMonth. We are sharing our new review on DNA methylation in melanoma immunotherapy and resistance exploring how to improve immune responses and therapies for patients. #Epigenetics #CancerResearch @MelanomaReAlli #dermtwitter
New review article on DNA methylation in melanoma immunotherapy: mechanisms and therapeutic opportunities.
Read full article here: doi.org/10.1186/s13148-025-0…
Only a subset of cancer patients currently respond to checkpoint inhibitors, partly due to an unfavorable tumor microenvironment. In a new Phase IB trial in Head and neck squamous cell carcinomas led by @DrSaraPai @YaleCancer
immuno-epigenetic therapy combining an FDA-approved DNA hypomethylating agent and checkpoint blockade resulted in favorable changes in the TME, including decreased Tregs, increased CD8+ infiltration,
increased IFN-γ signature and PD-L1 expression in a subset of patients. Although an early trial, hope for expanding the use of checkpoint inhibitors for cancer by using epigenetic approaches. jci.org/articles/view/181671
Thank you to @NatureCancer for featuring our journey @YaleCancer
Viewpoint now ONLINE! @NatureCancer
⭐️'The 2024 generation'
🔗nature.com/articles/s43018-0…
Don't miss this piece where 12 #ECRs who started their #cancerresearch labs in 2024 reflect on the experience so far, including the ups and downs of the journey, and their plans for the future.
Tune in for the latest on acral melanoma 🔬
We invite you to join us as MRA's CEO Dr. Marc Hurlbert sits down with Dr. Boris Bastian of the University of California, San Francisco, to discuss the rare melanoma subtypes and recent acral melanoma research updates led by Dr. Bastian himself.
Register: melanomaresearchalliance-org…
Thankful to all mentors @FlavellLab @MarcusBosenberg @LysoProteomics @billdamsky @bbmbisu on and off Twitter/X who helped make it happen.
Today is a big day for #melanoma research and patient care with the @US_FDA approval of the first T cell-based therapy for melanoma. Exciting possibilities ahead for "boosting" T cell effectiveness and developing the next generation of immunotherapies #dermtwitter